Bortezomib-D8 (Major) Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften

Off-White Solid

Verwenden

Labeled Bortezomib, whcih the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eu

Bortezomib-D8 (Major) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Bortezomib-D8 (Major) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Chemsky（shanghai）International Co.,Ltd.	021-50135380	shchemsky@sina.com	China	32321	50
Cato Research Chemicals Inc.	020-81960175	min.he@cato-chem.com	China	1955	55
LGC Science (Shanghai) Ltd.	17717235263	fan.yang@LGCgroup.com	China	18798	58
Shanghai Haohong Scientific Co., Ltd.	400-8210725 4008210725	malulu@leyan.com	China	39834	58
Santa Cruz Biotechnology Inc	--	scbt@scbt.com	China	6594	58

---

• Velcade-D8, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic Acid-D8
• Bortezomib-D8 (Major)
• C19H17D8BN4O4
• Inhibitors
• Boron Derivatives
• Intermediates & Fine Chemicals
• Isotope Labeled Compounds
• Pharmaceuticals
• Isotope Labelled Compounds